SCHEMBL14972506

SCHEMBL14972506

O=[N+]([O-])c1c(OS(=O)(=O)C(F)(F)F)ccc2c1CCCC2

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 5/20 0.35
DRD3 P35462 4/20 0.35
HTR1D P28221 2/20 0.35
GRIN2D O15399 1/20 0.33
GRIN3B O60391 1/20 0.33
GRIN1 Q05586 1/20 0.33
GRIN2A Q12879 1/20 0.33
GRIN2B Q13224 1/20 0.33
GRIN2C Q14957 1/20 0.33
GRIN3A Q8TCU5 1/20 0.33
METAP2 P50579 1/20 0.32
STS P08842 1/20 0.32
LMNA P02545 1/20 0.32
MAPK1 P28482 1/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
PTPN1 P18031 1/20 0.32
DRD1 P21728 2/20 0.31
DRD4 P21917 2/20 0.31
DRD5 P21918 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14972523 0.97 GRIN2D (0.36) DRD2DRD3HTR1DGRIN2DGRIN3B
SCHEMBL7030007 0.80 DRD2 (0.41) DRD2DRD3HTR1D
SCHEMBL23336944 0.78 DRD2 (0.38) DRD2DRD3HTR1DMETAP2STS
SCHEMBL8730062 0.77 TDP1 (0.45) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL1506665 0.77 DRD2 (0.37) DRD2DRD3HTR1DSTSDRD1
SCHEMBL9085508 0.76 HTR2A (0.35) DRD2DRD3HTR1DMETAP2LMNA
SCHEMBL21468494 0.76 PTPN1 (0.40) STSLMNAMAPK1RAB9ASMN1; SMN2
SCHEMBL12533492 0.75 DRD2 (0.38) DRD2DRD3HTR1DDRD1DRD4
SCHEMBL1820878 0.75 DRD2 (0.53) DRD2DRD3HTR1DDRD1DRD4
SCHEMBL25202499 0.74 GRIN2D (0.40) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240417379-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2024-12-19 US disclosed
US-12116351-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD (JP) 2024-10-15 US disclosed
US-20220380322-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2022-12-01 US disclosed
US-11434207-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD (JP) 2022-09-06 US disclosed
CN-108863959-B P2X4 receptor antagonists 日本化学药品株式会社 2021-11-30 CN disclosed
US-20200223806-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2020-07-16 US disclosed
CN-111333588-A P2X4 receptor antagonists 日本化学药品株式会社 2020-06-26 CN disclosed
US-10633349-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD (JP) 2020-04-28 US disclosed
CN-104066724-B P2X4 receptor antagonists 日本化学药品株式会社 2020-04-17 CN disclosed
US-20180201587-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2018-07-19 US disclosed
US-9382236-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD (JP) 2016-07-05 US disclosed
US-8962613-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD. (JP) 2015-02-24 US disclosed
US-20140357858-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2014-12-04 US disclosed
EP-2631229-B1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO (JP) 2014-12-03 EP disclosed
EP-2803662-A1 P2X4 RECEPTOR ANTAGONIST Nippon Chemiphar Co., Ltd. (JP) 2014-11-19 EP disclosed
US-8673915-B2 P 2×4 receptor antagonist NIPPON CHEMIPHAR CO., LTD. (JP) 2014-03-18 US disclosed
EP-2631229-A1 P2X4 RECEPTOR ANTAGONIST Nippon Chemiphar Co., Ltd. (JP) 2013-08-28 EP disclosed
US-20130178625-A1 P 2 X 4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD. (JP) 2013-07-11 US disclosed
US-20130172550-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD. (JP) 2013-07-04 US disclosed
EP-2597088-A1 P2X4 RECEPTOR ANTAGONIST Nippon Chemiphar Co., Ltd. (JP) 2013-05-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130178625-A1 P 2 X 4 RECEPTOR ANTAGONIST P2RX4, P2RX2, P2RY4 DRD2 302/4885DRD3 295/4885HTR1D 51/4885
US-20220380322-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 DRD2 407/4885DRD3 371/4885HTR1D 123/4885
US-20240417379-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 DRD2 381/4885DRD3 328/4885HTR1D 110/4885
US-12116351-B2 P2X4 receptor antagonist P2RX7, P2RX1, P2RX2 DRD2 407/4885DRD3 371/4885HTR1D 123/4885
US-20140357858-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 DRD2 407/4885DRD3 371/4885HTR1D 123/4885
US-20200223806-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 DRD2 407/4885DRD3 371/4885HTR1D 123/4885
US-11434207-B2 P2X4 receptor antagonist P2RX7, P2RX1, P2RX2 DRD2 407/4885DRD3 371/4885HTR1D 123/4885
US-20130172550-A1 P2X4 RECEPTOR ANTAGONIST P2RX4, P2RX3, P2RX7 DRD2 257/4885DRD3 277/4885HTR1D 63/4885
US-10633349-B2 P2X4 receptor antagonist P2RX7, P2RX1, P2RX2 DRD2 407/4885DRD3 371/4885HTR1D 123/4885
US-20180201587-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 DRD2 407/4885DRD3 371/4885HTR1D 123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.